Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis

Dupilumab is a human monoclonal antibody directed against the alpha subunit of the interleukin-4 receptor and inhibits the signaling of IL-4 and IL-13. It is approved for treating asthma and other type-2 inflammatory diseases. There is a conflict in the literature regarding the safety and efficacy o...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in pharmacology Vol. 13; p. 992731
Main Authors:	Zaazouee, Mohamed Sayed, Alwarraqi, Asmaa Gomaa, Mohammed, Yasmine Adel, Badheeb, Mohamed A, Farhat, Abdullah Mohamed, Eleyan, Mohammed, Morad, Afnan, Zeid, Marwa Abdel-Aziz, Mohamed, Aya Shaban, AbuEl-Enien, Hazem, Abdelalim, Ahmed, Elsnhory, Ahmed Bostamy, Hrizat, Yasmin S M, Altahir, Nagat Taha, Atef, Doaa, Elshanbary, Alaa Ahmed, Alsharif, Khalaf F, Alzahrani, Khalid J, Algahtani, Mohammad, Theyab, Abdulrahman, Hawsawi, Yousef M, Aldarmahi, Ahmed A, Abdel-Daim, Mohamed M
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 03-10-2022
Subjects:	asthma dupilumab meta-analysis monoclonal antibody Pharmacology systematic review meta-analysis asthma monoclonal antibody systematic review dupilumab
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Dupilumab is a human monoclonal antibody directed against the alpha subunit of the interleukin-4 receptor and inhibits the signaling of IL-4 and IL-13. It is approved for treating asthma and other type-2 inflammatory diseases. There is a conflict in the literature regarding the safety and efficacy of dupilumab. Thus, we aimed to assess the safety and efficacy of dupilumab in patients with moderate to severe asthma. Six databases (PubMed, Embase, Scopus, Web of Science, Cochrane library, and clinicaltrials.gov registry) were searched until January 2022. We included randomized controlled trials that compared dupilumab with the placebo in moderate to severe asthma patients. We extracted the data at 12 and 24 weeks and analyzed them using review manager 5.4. Thirteen trials were included. Dupilumab significantly improved the forced expiratory volume in 1 s, asthma control questionnaire score, the fraction of exhaled nitric oxide level, and immunoglobulin E level at 12 and 24 weeks ( < 0.05). However, it was associated with increased blood eosinophils at 12 and 24 weeks. Dupilumab was generally a safe agent for asthmatic patients. It showed no significant difference compared with the placebo regarding most adverse events. Dupilumab improves pulmonary function and reduces local and systemic inflammatory markers with minimal adverse events in patients with moderate to severe asthma.
Bibliography:	content type line 23 SourceType-Scholarly Journals-1 Marina Piscopo, University of Naples Federico II, Italy Sy Duong-Quy, Lam Dong Medical College, Vietnam This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology Reviewed by: Ashraf Abdel-Naim, Ain Shams University, Egypt Edited by: Ahmed Esmat Abdel Moneim, Helwan University, Egypt
ISSN:	1663-9812 1663-9812
DOI:	10.3389/fphar.2022.992731